Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    A phase II study of ifosfamide in endometrial cancer (1990)
    Springer
    Cancer chemotherapy and pharmacology 26 (1990), S. S4 
    Details
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Around 32% of all patients with endometrial carcinoma relapse after primary therapy. The outlook for these patients is poor. Ifosfamide (IFX) has activity in a number of gynaecological malignancies and was selected for evaluation in this disease. The aims of this study were to assess the activity and toxicity of IFX in recurrent endometrial carcinoma no longer amenable to radical local treatment. In all, 16 evaluable patients with symptomatic advanced metastatic or recurrent disease entered a phase II study of this drug. Patients received IFX (5 g/m2) as a 24-h infusion, with mesna (8 g/m2) given during and for 12 h following IFX to prevent urothelial toxicity. Treatment was repeated every 21 days. Two patients showed evidence of response [one complete response (CR) of 3 months and one partial response (PR) lasting 5 months]. Most patients experienced nausea and vomiting, and WHO grade 3/4 alopecia invariably occurred after two or more cycles. Four patients developed severe (grade 3/4) IFX/mesna CNS toxicity, and four other patients had mild (grade 1/2) CNS toxicity. Significant myelosuppression was seen in 3/41 cycles. Haematuria was uncommon and invariably mild. There were two toxic deaths (one due to grade 4 CNS toxicity and one due to septicaemia). IFX has activity in endometrial carcinoma, but responses are of limited duration and toxicity is considerable.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00685407
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Phase II studies of ifosfamide alone and in combination in cancer of the cervix (1990)
    Springer
    Cancer chemotherapy and pharmacology 26 (1990), S. S12 
    Details
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A series of phase II studies using ifosfamide (IFX) as a single agent and in combination with cisplatin and bleomycin (BIP) in advanced and recurrent cervical cancer have been coordinated at the West Midlands CRC Clinical Trials Unit (Birmingham, UK). The aims of these studies were to identify single agents and combination regimens that may be of value for palliation and have potential for use as neoadjuvant and adjuvant therapy at the time of primary treatment. A total of 79 patients with disease non-amenable to radical local therapy were treated with single-agent IFX or the BIP combination. In 30 patients treated with single-agent IFX, 10 objective responses (30%) were seen, with 1 complete response. In 49 patients treated with BIP, 34 objective responses (69%) were seen, with 10 complete responses (20%). Toxicity included alopecia, nausea and vomiting, myelosuppression, infection, reduction in renal function and disturbance of consciousness. These data indicate that IFX is highly active in cervix cancer and, in combination with bleomycin and cisplatin, can be used for effective palliation and cytoreduction in 〉70% of patients. IFX-containing regimens have potential for use as neoadjuvant and adjuvant therapy in patients at high risk of recurrence with conventional treatment. These hypotheses are currently being tested in prospective randomised trials.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00685409
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer (1990)
    Springer
    Cancer chemotherapy and pharmacology 26 (1990), S. S59 
    Details
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Patients with advanced and bulky early-stage cancer of the cervix have an unfavourable prognosis, which may be improved by initial neoadjuvant, cytoreductive chemotherapy. In a phase II study, coordinated at the West Midlands CRC Clinical Trials Unit, Birmingham, using ifosfamide (IFX) in combination with cisplatin and bleomycin (BIP) in advanced and recurrent cervical cancer, we demonstrated a response rate of 69%. This regimen produces rapid responses with acceptable toxicity and has potential for use as neoadjuvant therapy prior to radical radiotherapy in patients presenting with advanced and bulky early-stage disease. In an initial pilot study of this approach, 13 of 19 patients (68%) with primary inoperable disease showed significant tumour regression prior to radical local radiotherapy. Interim analysis of the first 66 patients entered into a randomized study evaluating the value of this approach has shown complete clinical tumour resolution after radical radiotherapy in 24/32 patients (75%) treated with up to three cycles of BIP prior to radiotherapy vs 19/34 patients (56%) treated with radiotherapy alone. There was no evidence that neoadjuvant chemotherapy enhances the acute toxic effects of pelvic radiotherapy. This approach has the potential for improving the outlook in patients with poor-prognosis primary disease.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00685422
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Placental transfer of chlorthalidone and its elimination in maternal milk (1978)
    Springer
    European journal of clinical pharmacology 13 (1978), S. 129-131 
    Details
    ISSN: 1432-1041
    Keywords: Chlorthalidone (Hygroton) ; placental transfer ; carbonic anhydrase binding ; distribution in blood ; elimination in milk
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary A gas chromatographic method has been used to determine chlorthalidone in amniotic fluid, maternal and foetal blood at delivery, and in maternal milk and blood three days after delivery, following the administration of chlorthalidone to nine pregnant women suffering from toxaemia of pregnancy. Placental transfer of chlorthalidone and elimination in maternal milk have been shown and the implications of these factors are discussed. An explanation has been proposed for our observations that foetal blood levels of the drug are about 15% of those in maternal blood.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00609757
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer (2000)
    Springer
    Annals of oncology 11 (2000), S. 1603-1608 
    Details
    ISSN: 1569-8041
    Keywords: cisplatin ; ovarian cancer ; paclitaxel ; sequential chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Purpose:To examine the activity and safety of two sequentiallyscheduled chemotherapy regimens comprising four cycles of paclitaxel (pctx)200 mg/m2/3 hours then four cycles of cisplatin (cisDDP) 100mg/m2, and vice versa, in patients with previouslyuntreated advanced ovarian cancer. Patients and methods:Between January 1994 and February 1996, werecruited 30 patients to the pctx-then-cisDDP regimen and 29 tocisDDP-then-pctx, in parallel phase II trials. Results:Both regimens were predictably active with responses seenin 22 of 30 patients (OR 74%; CR 27%, PR 47%) treatedwith pctx-then-cisDDP, as against 13 of 21 patients (OR 62%; CR38%, PR 24%) treated with cisDDP-then-pctx. The OR rate to fourcycles of pctx (induction) was 43%, with 27% diseaseprogression; the OR to four cycles of cisDDP (induction) was 57%, with5% progression. However, progression rates across both induction andconsolidation phases were 16% (pctx-then-cisDDP) and 29%(cisDDP-then-pctx). Both regimens were unacceptably neurotoxic, 11 patientssuffering grade 3 sensory neurotoxicity (5 on pctx-then-cisDDP, 6 oncisDDP-then-pctx) and 20 having grade 3 deafness (9 on pctx-then-cisDDP, 11on cisDDP-then-pctx). Conclusion:The activity of these sequential regimens justifiestheir further development using the less neurotoxic platinum analoguecarboplatin, perhaps combining paclitaxel with other platinum non-crossresistant drugs.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008343519687
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...